Résultats de la recherche

20 éléments trouvés pour «  »

  • Home | ECS progastrin

    Last Update : Feb 02, 2020 News: Events Jun 8 2 min hPG80 at ASCO 2021 - Prolevcan study Plasma hPG80 circulating prograstin levels in cancer patients in Nigeria: Prolevcan study Jun 8 3 min hPG80 at ASCO 2021 - Hepatocellular carcinoma ASCO Poster Session: Prognostic value of plasma hPG80, alone or in combination with AFP, in patients with hepatocellular carcinoma Apr 21, 2020 2 min A Major Publication: The Overexpression of hPG80 (circulating progastrin) in Multiple Cancers The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients Apr 21, 2020 1 min Dr. Aman Chauhan MD (Markey Cancer Center) speaking about hPG80 at #GI ASCO 2020 HPG80 (Progastrin), a novel blood-based biomarker for detection of neuroendocrine neoplasms. GI ASCO / Presented Friday, January 24, 2020

  • hPG80 | Main Scientific Publications | ECS progastrin

    Publications Last Posters hPG80 Main Scientific Publications Last updated: Jully 2, 2021 Prognostic Value of Plasma hPG 80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma ​ Jan, 2021 Simple Summary Metastatic renal cell carcinoma (mRCC) accounts for one-third of all newly diagnosed renal cell cancers. A better understanding of the biology and molecular basis of disease progression has resulted in several drug targets being identified and led to approval of several new drugs for treating mRCC in the past decade. A growing need has emerged for identifying novel molecular tumor biology based and stage-specific prognostic and predictive biomarkers in mRCC reflective of biology beyond the currently available prognostic models which are solely based on clinical characteristics. We investigated hPG 80 (circulating progastrin), which is associated with kidney cancer biology and found that hPG 80 levels is both an independent prognostic marker in mRCC and also improves current clinical prognostic models. This will help stratify mRCC patients more accurately in future and improve the management of mRCC patients. Abstract Precise management of kidney cancer requires the identification of prognostic factors. hPG 80 (circulating progastrin) is a tumor promoting peptide present in the blood of patients with various cancers, including renal cell carcinoma (RCC). In this study, we evaluated the prognostic value of plasma hPG 80 in 143 prospectively collected patients with metastatic RCC (mRCC). The prognostic impact of hPG 80 levels on overall survival (OS) in mRCC patients after controlling for hPG 80 levels in non-cancer age matched controls was determined and compared to the International Metastatic Database Consortium (IMDC) risk model (good, intermediate, poor). ROC curves were used to evaluate the diagnostic accuracy of hPG 80 using the area under the curve (AUC). Our results showed that plasma hPG80 was detected in 94% of mRCC patients. hPG 80 levels displayed high predictive accuracy with an AUC of 0.93 and 0.84 when compared to 18–25 year old controls and 50–80 year old controls, respectively. mRCC patients with high hPG 80 levels (>4.5 pM) had significantly lower OS compared to patients with low hPG 80 levels (<4.5 pM) (12 versus 31.2 months, respectively; p = 0.0031). Adding hPG 80 levels (score of 1 for patients having hPG 80 levels > 4.5 pM) to the six variables of the IMDC risk model showed a greater and significant difference in OS between the newly defined good-, intermediate- and poor-risk groups (p = 0.0003 compared to p = 0.0076). Finally, when patients with IMDC intermediate-risk group were further divided into two groups based on hPG 80 levels within these subgroups, increased OS were observed in patients with low hPG 80 levels (<4.5 pM). In conclusion, our data suggest that hPG 80 could be used for prognosticating survival in mRCC alone or integrated to the IMDC score (by adding a variable to the IMDC score or by substratifying the IMDC risk groups), be a prognostic biomarker in mRCC patients. Manish Kohli 1,*, Winston Tan 2, Bérengère Vire 3, Pierre Liaud 3, Mélina Blairvacq 3, Frederic Berthier 4, Daniel Rouison 4, George Garnier 4, Léa Payen 5, Thierry Cousin 6, Dominique Joubert 6 and Alexandre Prieur 6,* + Journals - Cancers - Volume 13 - Issue 3 - 10.3390/cancers13030375 The oncogenic and druggable hPG 80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients ​ Dec, 2019 EBiomedicine by THE LANCET déc. 2019 Authors : Benoit You Frédéric Mercier Eric Assenat Carole Langlois-Jacques Olivier Glehen Julien Soulé et al. In colorectal cancer, hPG80 (progastrin) is released from tumor cells, promotes cancer stem cells (CSC) self-renewal and is detected in the blood of patients. Because the gene GAST that encodes hPG80 is a target gene of oncogenic pathways that are activated in many tumor types, we hypothesized that hPG80 could be expressed by tumors from various origins other than colorectal cancers, be a drug target and be detectable in the blood of these patients. […] Research in context Evidence before study The National Cancer Institute recently highlighted the need forbiomarkers to improve early detection of cancers, monitor treatment effects and detect disease relapses. Therefore, the identification of a new tumor blood-based marker with broad expression across tumor types might have a significant impact on diagnostic and follow-up of patients. hPG80 (progastrin) was shown to be over-expressed in human colorectal tumor cells. Interestingly, GAST is a direct target of the Wnt/ß-catenin/Tcf4 oncogenic pathway. Since this pathway is activated inmany other cancers and plays a major function in cancer stem cells survival, we hypothesized that hPG80 (i) might be expressed by other types of cancers, and would be present in the blood of patients with tumors different from colorectal cancers and (ii) might be a drug target for various type of cancers. ​ Added value of this study Here we show that hPG80 is expressed by the tumor and present in the blood of 11 different types of cancer patients. Two retrospective kinetic studies where blood samples were collected regularly from cancer patients undergoing different treatments revealed strong associations between longitudinal hPG80 . ..... concentrations and anti-cancer treatment efficacy. We provide data showing the decrease of hPG80 after surgery in a cohort of patients with peritoneal involvements from gastroin-testinal cancers, treated with peri-operative chemotherapy regimens and cytoreductive surgery. We also show the correlationbetween hPG80 levels and standard imaging in a cohort of patients with hepatocellular carcinoma, managed with local or systemic treatments, including patients with no detectable levels of alpha-fetoprotein. Finally, we show that targeting hPG80 with our humanized antibody decreases self-renewal capacity of cancer stem cells from various origins. ​ Implications of all available evidence The technology we developed to detect hPG80 in the blood isr obust, reliable and inexpensive, making this test easy to implement by oncologists. This technology could be used to improve early cancer diagnosis and treatment efficacy monitoring. Furthermore, in this study we show that our anti-hPG80 therapeutic antibody, that was initially found to target the Wnt pathway and decrease self-renewal capacity in cancer stem cells from colorectal cancer, is envisioned to have the same effect on tumors from other origins. + Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening ​ Sep, 2017 Gastroenterology, 2017 September Authors : Anton Gies1, Katarina Cuk2, Petra Schrotz-King1, Hermann Brenner A variety of fecal immunochemical tests (FITs) for hemoglobin (Hb) are used in colorectal cancer screening. It is unclear to what extent differences in reported sensitivities and specificities reflect true heterogeneity in test performance or differences in study populations or varying pre-analytical conditions. We directly compared the sensitivity and specificity values with which 9 quantitative (laboratory-based and point-of-care) FITs detected advanced neoplasms (AN) in a single colorectal cancer screening study. […] + Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. ​ Dec, 2016 JAMA Oncol. 2016 Dec 3. Authors : Global Burden of Disease Cancer Collaboration, Fitzmaurice, Allen, Barber, Barregard, Bhutta, Brenner, Dicker .../... Zaid i, Zaki, Zenebe, Murray, Naghavi. Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. OBJECTIVE: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015. […] + Progastrin a new pro-angiogenic factor in colorectal cancer ​ Jun, 2015 Oncogene. 2015 June Authors : Najib S1, Kowalski-Chauvel A1, Do C1, Roche S2, Cohen-Jonathan-Moyal E3, Seva C1.Angiogenesis is essential in tumor progression and metastatic process, and increased angiogenesis has been associated with poor prognosis and relapse of colorectal cancer (CRC). VEGF has become the main target of anti-angiogenic therapy. However, most patients relapse after an initial response or present a resistance to the treatment. Identification of new pro-angiogenic factors may help to improve anti-angiogenic therapy. In this study, we demonstrated that the pro-hormone progastrin (PG), over-expressed in[…] + Wnt Signaling in Cancer ​ May, 2012 Cold Spring Harb Perspect Biol. 2012 MayAuthors : Paul PolakisAberrant regulation of the Wnt signaling pathway is a prevalent theme in cancer biology. From the earliest observation that Wnt overexpression could lead to malignant transformation of mouse mammary tissue to the most recent genetic discoveries gleaned from tumor genome sequencing, the Wnt pathway continues to evolve as a central mechanism in cancer biology. This article summarizes the evidence supporting a role for Wnt signaling in human cancer. This includes a review of […] + Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis ​ Aug, 2000 J Clin Invest. 2000 August Authors : Theodore J. Koh,1 Clemens J. Bulitta,1 John V. Fleming,1 Graham J. Dockray,2 Andrea Varro,2 and Timothy C. Wang1Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene occur in most colorectal cancers and lead to activation of β-catenin. Whereas several downstream targets of β-catenin have been identified (c-myc, cyclin D1, PPARδ), the precise functional significance of many of these targets has not been examined directly using genetic approaches. Previous studies have shown that […] + Targeting the Wnt pathway and cancer stem cells with anti-progastrin humanized antibodies: a major breakthrough for K-RAS mutated colorectal cancer treatment ​ Jun, 2017 Clinical Cancer Research, 2017 JuneAuthors : Alexandre Prieur, Monica Cappellini, Guillaume Habif, Marie-Paule Lefranc, Thibault Mazard, Eric Morency, Jean-Marc Pascussi, .../... Chris Planque, Eric Assenat, Frédéric Bibeau, Jean-François Bourgaux, Pascal Pujol, Alain Sézeur, Marc Ychou and Dominique JoubertPatients with metastatic colorectal cancer (CRC) suffer from disease relapse mainly due to cancer stem cells (CSC). Interestingly, they have an increased level of blood progastrin, a tumor-promoting peptide essential for[…] + Autocrine Secretion of Progastrin Promotes the Survival and Self-Renewal of Colon Cancer Stem-like Cells. ​ Jun, 2016 Cancer Res. 2016 June Authors : Giraud, Failla, Pascussi, Lagerqvist, Ollier, Finetti, Bertucci, Ya, Gasmi, Bourgaux, Prudhomme, Mazard, Ait-Arsa, Houhou, Birnbaum, Pélegrin, Vincent, Ryall, Joubert, Pannequin, Hollande.Subpopulations of cancer stem-like cells (CSC) are thought to drive tumor progression and posttreatment recurrence in multiple solid tumors. However, the mechanisms that maintain stable proportions of self-renewing CSC within heterogeneous tumors under homeostatic conditions remain poorly understood. Progastrin is a secreted peptide that exhibits tumor-forming potential in colorectal cancer, where it regulates pathways known to modulate colon CSC behaviors. In this study, we investigated the role of progastrin in […] + Novel roles of gastrin ​ Jul, 2014 J Physiol. 2014 Jul 15Authors : Dimaline, VarroThe existence of the hormone gastrin in the distal stomach (antrum) has been known for almost 110 years, and the physiological function of this amidated peptide in regulating gastric acid secretion via the CCK2 receptor is now well established. In this brief review we consider important additional roles of gastrin, including regulation of genes encoding proteins such as […] + The wnt target jagged-1 mediates the activation of notch signaling by progastrin in human colorectal cancer cells. ​ Aug, 2009 Cancer Res. 2009 August Authors : Julie Pannequin, Caroline Bonnans, Nathalie Delaunay, Joanne Ryan, Jean-François Bourgaux, Dominique Joubert and Frédéric Hollande The Wnt and Notch signaling pathways are both abnormally activated in colorectal cancer (CRC). We recently showed that progastrin depletion inhibited Wnt signaling and increased goblet cell differentiation of CRC cells. Here, we show that progastrin down-regulation restores the expression by CRC cells of the early secretory lineage marker Math-1/Hath-1 due to […] + Expression but incomplete maturation of progastrin in colorectal carcinomas ​ Apr, 1993 Gastroenterology. 1993 April Authors : Van Solinge WW1, Nielsen FC, Friis-Hansen L, Falkmer UG, Rehfeld JF.To evaluate the hypothesis that gastrin is a local growth factor in colonic carcinomas, the expression of gastrin messenger RNA (mRNA) and peptides were examined in five human colon carcinoma cell lines, 12 solid colon carcinomas, and normal colonic tissue... […] + Common pitfalls in preclinical cancer target validation ​ May, 2017 Nature reviews, 2017 May Authors : William G. Kaelin JrAn alarming number of papers from laboratories nominating new cancer drug targets contain findings that cannot be reproduced by others or are simply not robust enough to justify drug discovery efforts. This problem probably has many causes, including an underappreciation of the danger of being misled by off-target effects when using pharmacological or genetic perturbants in complex biological assays. This danger is particularly acute when, as is often the case in cancer pharmacology, the biological phenotype being measured is a […] + The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies ​ Feb, 2016 Lab Invest. 2016 February Yang, Wang, Zhang, Wang, Nan, Li, Zhang, Mohammed, Haydon, Luu, Bi, He.he canonical WNT/β-catenin signaling pathway governs a myriad of biological processes underlying the development and maintenance of adult tissue homeostasis, including regulation of stem cell self-renewal, cell proliferation, differentiation, and apoptosis. WNTs are secreted lipid-modified glycoproteins that act as short-range ligands to activate receptor-mediated signaling pathways. The hallmark of the […] + Gastric secretion ​ Nov, 2013 Curr Opin Gastroenterol. 2013 NovAuthors : Shijian Chu;Mitchell Schubert;The review summarizes the past year's literature, basic science and clinical, regarding the neural, paracrine, hormonal, and intracellular regulation of gastric acid secretion.[…] + Beta-catenin/Tcf-4 inhibition after progastrin targeting reduces growth and drives differentiation of intestinal tumors ​ Nov, 2007 Clinical Cancer Research, 2017 JuneAuthors : Alexandre Prieur, Monica Cappellini, Guillaume Habif, Marie-Paule Lefranc, Thibault Mazard, Eric Morency, Jean-Marc Pascussi, .../... Chris Planque, Eric Assenat, Frédéric Bibeau, Jean-François Bourgaux, Pascal Pujol, Alain Sézeur, Marc Ychou and Dominique JoubertPatients with metastatic colorectal cancer (CRC) suffer from disease relapse mainly due to cancer stem cells (CSC). Interestingly, they have an increased level of blood progastrin, a tumor-promoting peptide essential for[…] + A synthesis of the knowledge of progastrin is available on the website of the Progastrin cancer control association. . + hPG80 Last Posters 2021 ANNUAL MEETING Poster Session : Prognostic value of plasma hPG80, alone or in combination with AFP in patients with hepatocellular carcinoma + Download the Poster 2020 Gastro Intestinal Cancers Symposium 628 Poster Session (Board #G9 ) : HPG80 (Progastrin), a novel blood-based biomarker for detection of neuroendocrine neoplasms. + Download the Poster 2019 ANNUAL MEETING 2294 / 23 - Plasma progastrin level as a predictive and prognostic biomarker in advanced prostate cancer + Download the Poster 2021 ANNUAL MEETING Plasma hPG80 (circulating Progastrin) levels in cancer patients in Nigeria: Prolevcan study + Download the Poster 2019 ANNUAL MEETING 3037 / 29 - Progastrin, a novel ubiquitous cancer blood biomarker for early detection and monitoring. + Download the Poster 2019 ANNUAL MEETING 2222 / 11 - Progastrin a new biomarker for hepatocellular cancer patient follow-up + Download the Poster 2021 ANNUAL MEETING Poster Session : hPG80 (Progastrin), a novel blood-based biomarker for detection of neuroendocrine neoplasms. + Download the Poster 2019 ANNUAL MEETING 2289 / 18 - Prognostic impact of progastrin levels in blood compared to MSKCC based clinical prognosis in metastatic renal cell cancer patients + Download the Poster 2018 ANNUAL MEETING 119P - Progastrin, a new blood biomarker for the diagnostic and therapeutic monitoring, in G.I. cancers: A BIG-RENAPE project. + Download the Poster

  • Press Corner | hPG80 | Cancer | DxPG80 | ECS Progastrin

    Press Corner PRESS ENQUIRIES ➜ Contact us via e-mail Subscription Welcome to our press mailing list OUR HISTORY ➜ From the lab to the patient Last updated: August 3, 2020 PHOTOS & LOGOS PHOTOS & LOGOS VIDEOS VIDEOS PRESS RELEASES Jun 8 2 min hPG80 at ASCO 2021 - Prolevcan study Plasma hPG80 circulating prograstin levels in cancer patients in Nigeria: Prolevcan study Jun 8 3 min hPG80 at ASCO 2021 - Hepatocellular carcinoma ASCO Poster Session: Prognostic value of plasma hPG80, alone or in combination with AFP, in patients with hepatocellular carcinoma PRESS RELEASES PRESS RELEASES VIDEOS VIDEOS PHOTOS & LOGOS Icone Logo format: Illustrator picture Logo_Puce 2020.ai PHOTOS & LOGOS PHOTOS & LOGOS VIDEOS PRESS RELEASES PRESS RELEASES Dominique Joubert Presentation Video length : 2:30' French (English subtitle) Royalty-free video on demand ​ From the lab to the patient Performing a scientific demonstration and bringing it to the patient is the dream of every scientist that Dominique Joubert is living. The scientific demonstration in question here is a major precision: to be able to detect cancer and to reverse the tumour process, in other words, to "bring back to normal cells that were cancerous" . Our Montpellier laboratory Video length : 1:01' Video without audio royalty-free video on demand ​ ​ Lyon CHU laboratory Video length : 3:06' Video without audio royalty-free video on demand ​ ​ It's time to control cancer Contact us Send Your message has been sent.

  • News | hPG80 | Cancer | DxPG80 | ECS Progastrin

    News Last updated: August 3, 2020 Jun 8 2 min hPG80 at ASCO 2021 - Prolevcan study Plasma hPG80 circulating prograstin levels in cancer patients in Nigeria: Prolevcan study Jun 8 3 min hPG80 at ASCO 2021 - Hepatocellular carcinoma ASCO Poster Session: Prognostic value of plasma hPG80, alone or in combination with AFP, in patients with hepatocellular carcinoma Apr 21, 2020 2 min A Major Publication: The Overexpression of hPG80 (circulating progastrin) in Multiple Cancers The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients Apr 21, 2020 1 min Dr. Aman Chauhan MD (Markey Cancer Center) speaking about hPG80 at #GI ASCO 2020 HPG80 (Progastrin), a novel blood-based biomarker for detection of neuroendocrine neoplasms. GI ASCO / Presented Friday, January 24, 2020

  • Home | hPG80 - A major target against Cancer | ECS Progastrin

    Last updated: August 3, 2020 HOWEVER The real battle against cancer is fought by physicians and patients! Our mission is simply to provide healthcare professionals with innovative tools that are the most reliable and effective possible. The hPG 80 blood biomarker has now been shown to be both a major weak point of cancer and a fundamental target to providing physicians with multiple solutions, now and in the future * : In cancer, hPG 80 is overexpressed in the tumor and detectable in the patient’s blood [1] . 16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date [1] . ​ Cancer stem cells express elevated levels of hPG 80 (circulating progastrin) [2][3] . Secretion of hPG 80 maintain tumor-initiating and self-renewal capabilities of cancer stem cells [3] . hPG 80 is released from the tumor and becomes detectable in the blood across all stages [3][4] . Plasma hPG 80 is elevated in a wide range of cancer patients [5] hPG 80 is produced by all cancer cells, but in quantities 100 to 1000 times higher by cancer stem cells [2] , making hPG 80 the only blood biomarker that gives information on tumor activity. BIBLIOGRAPHY [1]. You et al, EBioMedicine, 2020 Jan;51:102574 [2]. Giraud et al, Cancer Res, 2016;76(12):3618-28 [3]. Siddheshwar et al, Gut, 2001 Jan; 48(1): 47–52 [4]. Prieur et al, Clin Cancer Res. 2017;23(17):5267–5280 [5]. Konieczkowski et al, Cancer Cell, 2018 May 14;33(5):801-815 KEY FACTS CURRENT AND PROSPECTIVE CLINICAL APPLICATIONS CURRENT FOLLOW UP hPG 80 measurement, and its trend, from simple blood samples, can help Physicians in the follow-up of patients, providing them with additional meaningful information on: treatment efficacy , risk of minimal residual disease, risk of relapse. CURRENT DIAGNOSIS The presence or absence of hPG 80 in blood can also provide Physicians with an additional indicator of vigilance for earlier diagnosis , especially for at-risk populations and for cancers for which no biomarker exists . PROSPECTIVE OTHER USES In addition, other potential uses for hPG 80 are being investigated and will be available to physicians in a few years: hPG 80 neutralization has shown that it can lead to a new clinical approach to tumor reversion therapy that causes cancer cells to return to “normal”, hPG 80 can provide a major breakthrough in tumor localization by PET Scan imaging, Finally, the robustness of its detection in blood makes it possible to envisage in the short term the production of a hPG 80 rapid test providing physicians and health authorities with a new affordable and very minimally invasive tool that could help them in their early detection strategies. NOW AVAILABLE TO PHYSICIANS A NEW TOOL : The blood test for detection and measurement of the target hPG80 Learn more... AVAILABLE ONLY ON MEDICAL PRESCRIPTION Contact Us Medical Doctor / Docteur en médecine Medical Professor / Professeur en médecine Mr. / M Ms. / Mme I fully read and agree to the privacy policy. / J'ai lu et j'accepte les clauses de confidentialité. Send / Envoyer Thank you for your message / Merci pour votre message

  • hPG80 & Cancer | hPG80 for Peritoneal Carcinomatosis | ECS Progastrin

    Contract signed with: Les Hospices Civils de Lyon ​ Principal investigator: Benoît You hPG 80 is a biomarker for patients treated for gastro-intestinal cancers. A retrospective study on the BIG-RENAPE cohort. Last updated: August 3, 2020 1 Scientific context There is a need for early predictor of clinical benefits able to compress the time line required to evaluate new treatments ( 1) . Moreover, peritoneal carcinomatosis frequently developed by gastrointestinal cancer patients is poorly assessable using conventional imaging ( 2) . In addition, the traditional morphological RECIST criteria were found not adequate for assessing treatment efficacy with anti-angiogenic drugs ( 3) . Strategies that may help characterize tumor size changes or treatment efficacy during treatment are to be developed. If some serum markers (liquid biopsy) were shown to be surrogate markers of treatment efficacy, they could be used to identify the patients who benefit the most from the treatment or who may be candidates for iterative surgery ( 4) . 2 hPG80, a new blood based biomarker Non Pathologic Condition hPG 80 is not found in the blood of healthy people. When progastrin is maturated into gastrin, it is released from the cells. ​ When gastrin is produced by the G cells of the stomach antrum, it plays its role to control acidic secretions during digestion. Pathologic Condition hPG 80 is detected in the blood of cancer patients. When progastrin is not maturated into gastrin, it is released from the cells as such and named hPG 80 . ​ This only happens in tumor cells, whatever the tumor cell: progastrin becomes a circulating protein, hPG 80 , which can be detected in the blood of cancer patients. 3 Objective Assessment of hPG80 usability in follow up with surgery. 4 Patients Patients recorded in prospective BIG-RENAPE project database, NCT02823860 (Lyon, FRANCE). Biological data were extracted from the data base. Analysis was performed in HCL Lyon Sud facility (Pierre-Bénite, FRANCE). 194 patients with peritoneal involvements from gastrointestinal cancers, treated with peri-operative chemotherapy regimens and cytoreductive surgery. ​ Blood samples were collected at inclusion (n=194) and between 8 and 24 hours after cytoreductive surgery, performed with or without hyperthermic intraperitoneal chemotherapy (HIPEC) (n=85). 5 Results In this cohort, median hPG80 significantly decreased from inclusion to the post-operative period from 3.08 to 1.57 pM[AP1] , p<0.0001 with two-tailed unpaired Mann-Whitney test. ​ The individual curves showed that 74.2% of patients had hPG80 titer declines >25%. The remaining patients experienced stable concentrations (16.1% of patients), or hPG80 level increases >25% (9.7% of patients). 6 Conclusion hPG80 is a good biomarker for peritoneal carcinomatosis patients to assess surgery efficacy. Levels are significantly decreased after surgery and individual follow-up shows that minimal residual disease might be questioned via the presence of hPG80 in the blood. ​ These results have been published in You et al, EBioMedicine, 2020 . 7 Bibliography 1 . Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-5, 2004. 2 . Laghi A, Bellini D, Rengo M, et al: Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis. Radiol Med 122:1-15, 2017. ​ 3 . Nishino M, Jagannathan JP, Krajewski KM, et al: Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198:737-45. ​ 4 . McMullen JRW, Selleck M, Wall NR, et al: Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget 8:43481-43490, 2017. ​ 5 . You B, Mercier F, Assenat E, et al : The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine 51:102574, 2020.

  • Terms | ECS progastrin

    Informations et Mentions légales / Conditions d'utilisation du Site Internet. Informations et Mentions légales et Termes et Conditions d'Utilisation du Site Internet. ​ ​ En accédant, visitant ou utilisant ce site internet, vous acceptez de vous soumettre et d'être lié par les présentes "Informations Légales et Termes et Conditions d'Utilisation du Site Internet" (ci-après les "Informations Légales"). Les Informations Légales régissent uniquement le site internet de la société ECS Progastrin SA, accessible à l'adresse https://www.ecs-progastrin.com (ci-après le "Site Internet"). D'autres termes et conditions sont applicables aux autres sites internet du Groupe Progastrine invest (le terme "Groupe Progastrine invest" correspond à l'ensemble des sociétés composée de Progastrine invest SCSp et de toutes ses filiales, affiliés ou succursales) et nous vous invitons à lire ces termes et conditions lors de votre visite sur ces autres sites internet du Groupe Progastrine invest. ​ Afin de se conformer aux lois et règlements en vigueur dans votre pays de résidence, nous attirons votre attention sur le fait que le contenu du Site Internet, conformément à l'avertissement mis en évidence sur la page d'accueil du Site, est réservé exclusivement aux professionnels habilités dans leurs pays à exercer la médecine. Si vous n'êtes pas un professionnel de santé habilités dans votre pays à exercer la médecine, vous n'êtes pas autorisés à aller plus loin et vous devez quitter ce Site Internet immédiatement. L'accès au Site Internet est interdit à toute personne domiciliée ou résidant dans un pays dans lequel l'utilisation ou l'accès à ce Site Internet serait contraire aux lois et réglementations applicables. Si vous êtes domiciliés ou résidez dans un tel pays, vous n'êtes pas autorisés à aller plus loin et vous devez quitter ce Site Internet immédiatement. Le Site comprend également des informations scientifiques ou commerciales sur des dispositif médicaux de diagnostic in vitro. Lesdites informations sont publiées sur le Site à titre informatif uniquement et à destination uniquement des professionnels de santé autorisé à exercer la médecine qui seraient désireux d'obtenir des informations sur les solutions proposée par ECS Progastrin, le Groupe Progastrine invest ou ses filiales, affiliés ou sucursales. Les informations présentées sur ce site n'étant pas destinées au grand public, elles ne remplacent pas l'avis du médecin ou du pharmacien qui seuls sont habilités dans leurs domaines respectifs à effectuer un diagnostic médical de toute maladie ou problème physique ou pour prescrire ou utiliser des médicaments présentés sur le Site. Le Site n'est ni destiné à être utilisé pour signaler des problèmes de santé, des effets indésirables ou pour déposer des réclamations techniques concernant les produits de ECS Progastrin, ni destiné à poser des questions techniques ou médicales concernant lesdits produits. Dans tous les cas, nous vous conseillons de consulter votre médecin ou votre pharmacien. ​ En poursuivant sa navigation sur le site et après avoir été vivement invité à lire les présentes Informations Légales, l'utilisateur confirme de s'être assuré d'être parfaitement habilité à utiliser ce site et dégage totalement l'éditeur du Site de toute responsabilité liée à une utilisation non conforme aux réglementations en vigueur dans le pays de l'utilisateur. ​ ​ Les Informations Légales peuvent être occasionnellement amendées par ECS Progastrin. Vous êtes donc invités à les consulter périodiquement. ​ Le présent site web, accessible à partir de l’adresse URL www.ecs-progastrin.com (ci-après le « Site ») est édité par : ECS-Progastrin, Chemin de la Meunière 12, 1008 Prilly – Suisse RC du canton de Vaud numéro CHE - 243.597.027 Tél.: +41 (0)21 625 06 37 E-mail : contact[@]ecs-progastrin[dot]com Directeur de la publication : Éric Thieulin Hébergeur Wix.com Inc. ⏐ 500 Terry A François Blvd San Francisco, CA 94158 Téléphone : +1 415-639-9034. Vous avez des questions, des commentaires ou des suggestions concernant notre site Internet ? Écrivez-nous à l’adresse suivante : it[at]ecs-progastrin[dot]com ​ ​ ​ Propriété intellectuelle Le Site Web, sa structure générale, et chacun des éléments qui le compose, et notamment les textes, articles, lettres d’informations, communiqués, présentations, brochures, illustrations, dessins, graphismes, photographies, programmes informatiques, animations, etc. sont la propriété intellectuelle exclusive de ECS-Progastrin. L’ensemble de ce Site relève de la législation Suisse et internationale sur les droits d’auteur et de la propriété intellectuelle. Les noms, marques et enseignes cités sur ce site sont la propriété de leurs déposants respectifs. Toute utilisation ou reproduction, totale ou partielle, du site, des éléments qui le composent et/ou des informations qui y figurent, par quelque procédé que ce soit, constitue une contrefaçon sanctionnée par le Code de la propriété intellectuelle Suisse. Les Utilisateurs ne sont autorisés qu’à représenter le Site Web sur l’écran de leur ordinateur personnel, imprimer les pages du Site Web pour leur usage personnel et reproduire temporairement les fichiers qui le constituent dans la mémoire cache de cet ordinateur aux seules fins de faciliter la consultation du Site Web. Par exception à l’alinéa précédent, ECS-Progastrin autorise les Utilisateurs à télécharger sur le disque dur de leur ordinateur les documents qui sont mis à la disposition des Utilisateurs sous la forme de fichiers électroniques spécifiquement en vue de leur téléchargement. Ces fichiers ne peuvent être téléchargés qu’à partir de liens hypertextes reproduisant la mention « télécharger ce document ici » ou toute autre mention manifestant l’autorisation donnée aux Utilisateurs de télécharger ces fichiers. Dans ce cas, et sauf disposition contraire expresse reproduite sur chacun des documents susvisés, l’Utilisateur est autorisé à détenir une copie de ces documents et à les imprimer pour un usage strictement privé. Il s’interdit en particulier de diffuser à des tiers ces documents par impression et distribution sur un support tangible et par mise à disposition sur un serveur installé sur un réseau public ou privé. ​ ​ Autres dispositions Le Site ECS-Progastrin est réservé à l’usage privé de chaque Utilisateur. La langue de référence du site ECS-Progastrin est le français. ECS-Progastrin ne pourra être tenu pour responsable de toute erreur produite ou malentendu engendré à l’occasion des traductions présentes sur le site. Le Site ECS-Progastrin et les données, informations et documents qu’il fournit n’ont qu’une vocation d’information générale sur les activités d’ECS-Progastrin et ne peuvent en aucun cas être considérés comme constituant un acte de conseil (technique, scientifique, juridique, comptables, commerciales, fiscales , financières, etc.), une sollicitation et/ou une offre de services. Chaque Utilisateur est seul responsable de l’usage qu’il fait des informations fournies à partir du Site Web et ECS-Progastrin ne pourra en aucun cas être tenu responsable de tous dommages directs ou indirects découlant de l’utilisation de ces informations par l’Utilisateur. ECS-Progastrin ne garantit pas que le Site Web sera accessible de manière continue. Les sites web de tiers, leur contenu et/ou les documents accessibles à partir des liens hypertextes publiés sur le Site Web ou dans les documents téléchargeables à partir de ce dernier sont la responsabilité exclusive de leur(s) auteur(s) et ne sauraient engager la responsabilité d’ECS-Progastrin. Les Utilisateurs ne sont pas autorisés à créer un lien hypertexte vers le Site Web et/ou une page quelconque du Site Web et/ou d’un fichier s’y trouvant sans l’accord préalable et exprès d’ECS-Progastrin.

  • DxPG80 | IVD test for hPG80 measurement | ECS progastrin

    ​ DxPG 80 HOW-TO GUIDE (FRANCE) Human circulating Progastrin (hPG80) Immunoassay ​ ​ ​ The DxPG80 Elisa test DxPG80 IVD test how-to guide Prescription​ ​ Last updated: August 3, 2020 Access to this page is restricted to healthcare professionals only The DxPG 80 test is an ELISA (Enzyme-Linked Immunosorbent Assay) for the detection of hPG 80 (circulating human progastrin). The test is intended for professional laboratory use only. ​ Please note that for greater clarity, we use the name hPG 80 , referring to extracellular Progastrin. The test is based on the principle of a sandwich ELISA to measure the concentration of hPG 80 in plasma samples that have been collected in EDTA tubes. Briefly, a capture antibody specific for hPG 80 is immobilised on the 96-well plate. The hPG 80 present in the calibrators and samples added to the wells will bind to the immobilized capture antibody. The test plate includes calibrators which are used to estimate the level of hPG 80 in EDTA plasma samples. The wells are washed and an anti- hPG 80 detection antibody coupled to horseradish peroxidase (HRP) is added, resulting in an antibody-antigen-antibody complex. After a second wash, a substrate solution of 3,3',5,5'-Tetramethylbenzidine (TMB) is added to the wells, producing a blue colour directly proportional to the amount of hPG 80 present in the initial sample. The Stop Solution changes the colour from blue to yellow, and the wells are read at 450 nm with a microplate reader. The assay is technically characterised in manual mode by a limit of detection (LOD, 1 pM) and a limit of quantification (LOQ, 3.3 pM). The LOD detects the presence of hPG 80 and the LOQ gives the concentration at which the assay is quantitative. ​ Table 1 : Comparative description of hPG 80 in Controls (healthy blood donors 18-40 years old at low risk of cancer) and Cancer patients (16 cancers tested, all combined)[1]. Reference range are given for a 2.5 (low range) and 97.5 (high range) percentile. IQR: Inter-Quartil Range, 25-75%. SE: Standard Error. BIBLIOGRAPHY [1]. You et al, EBioMedicine, 2020 Jan;51:102574 From the blood test to reporting the result to the physician:

  • Download | hPG80 | ECS-Progastrin

    Download Last updated: August 3, 2020 Our job is only to produce and market innovative tools for physicians. They then identify and define the best way to use our tools. For this reason, we invite you to follow this link to visit the "Physician & Patient Support" page of the Progastrin Cancer Control Association 's website, an association of healthcare professionals that collects, enhances and diffuses knowledge about hPG80 and its usefulness in the fight against cancer. ​ Documents presently available : White paper on the link between hPG 80 (circulating Progastrin) and cancer Physicians' booklet Leaflet for doctors to give to their patients General and pathological data sheets

  • | ecs-progastrin.com

    legal DISCLAIMER Are you a healthcare professional? Every effort is made to ensure that the material contained in this website is accurate and timely. However, we wish to make it clear first and foremost that the information provided is not intended to replace the assistance, advice, diagnosis or treatment provided by physicians and may not be applicable in all cases or countries. The part of the website that you wish to access may contain information reserved solely for doctors who wish to obtain details of the solutions offered by ECS Progastrin. This is why, by continuing to browse the site and after having been invited to read this legal information, the user declares that she/he is herself/himself a healthcare professional, confirms that she/he has ensured that she/he is fully authorised to use this site and releases the site publisher from any liability related to any use that does not comply with the regulations in force in the user's country. I AM NOT A HEALTHCAR PROFESSIONAL I AM A HEATHCARE PROFESSIONAL Terms and conditions